RankingsPricing
  1. US-listed companies
  2. NeuBase Therapeutics, Inc.
  3. Financials
  4. Cash from financing

NeuBase Therapeutics, Inc.NBSE

Market cap
$1.41M
P/E ratio
SummaryFinancials
Period EndCash from financing (Million USD)YoY (%)
Sep 30, 2022-0-100.61%
Sep 30, 202142+27.89%
Sep 30, 202033+143.51%
Sep 30, 201914-15859.85%
Sep 30, 2018-0-100.44%
Sep 30, 201719-13068.20%
Sep 30, 2016-0-100.57%
Sep 30, 201526+55.87%
Sep 30, 201417+45.06%
Sep 30, 201312+79.45%
Sep 30, 20127+153.69%
Sep 30, 20113

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating income Operating expenses Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSAdjusted EPSDividend payout ratio (%)Dividend per shareAdjusted DPSEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)